Investors of MoonLake Immunotherapeutics Gains Chance to Lead Securities Fraud Case
Investor Opportunity in MoonLake Immunotherapeutics Fraud Case
In recent developments, the Rosen Law Firm, a recognized name in investor rights, has brought attention to a significant opportunity for investors of MoonLake Immunotherapeutics (NASDAQ: MLTX). The firm is reaching out to those who purchased common stock between March 10, 2024, and September 29, 2025, urging them to consider joining a class action lawsuit centered on alleged securities fraud.
Importance of the Deadline
The deadline to act as a lead plaintiff is set for December 15, 2025. Investors who bought shares within the defined
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.